Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02624804 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study of the Therapeutic Potential of Stem Cell Educator Therapy in Type 1 Diabetes
A Phase 1 study, sponsored by Hackensack Meridian Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT02624804: Completed Phase 1 study, sponsored by Hackensack Meridian Health.
NCT02624804 is a Phase 1 study that has completed, run by Hackensack Meridian Health. The registered enrollment target is 13 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02624804, a Phase 1 study, has completed, sponsored by Hackensack Meridian Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a prospective, single arm, open-label, single-center pilot study to assess the safety, feasibility, and efficacy of Stem Cell Educator therapy for the treatment of patients with Type 1 Diabetes.
Primary Outcome
The primary study endpoint will be the occurrence of treatment-related adverse effects. Adverse events that occur during therapy (especially those that necessitate temporary or permanent discontinuation of therapy) and over the 12-month follow-up period will be assessed.
Interventions
- BIOLOGICAL Stem Cell Educator Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2017-06-27 |
| Est. Completion | 2024-03-11 |
| Phase | Phase 1 |
What the finished NCT02624804 record still lists
NCT02624804 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 1 intervention - of which Stem Cell Educator Therapy is the first listed.
NCT02624804 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02624804 about?
NCT02624804 is a clinical study titled "A Pilot Study of the Therapeutic Potential of Stem Cell Educator Therapy in Type 1 Diabetes". This is a prospective, single arm, open-label, single-center pilot study to assess the safety, feasibility, and efficacy of Stem Cell Educator therapy for the treatment of patients with Type 1 Diabetes.
What is the current status of trial NCT02624804?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2017-06-27. Estimated completion is 2024-03-11.
What interventions are being tested in trial NCT02624804?
The interventions under investigation include: Stem Cell Educator Therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT02624804?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02624804's enrollment target sits among peer trials
13 1847th of 2000 higher than 149 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI